New drug cocktail shows promise in battling advanced head and neck cancer

NCT ID NCT05784012

Ongoing Disease control Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two drugs, niraparib and dostarlimab, to standard radiation therapy can better control advanced head and neck cancer. About 34 adults with stage III or IV cancer will receive the drugs before, during, and after radiation. The goal is to see if this combination improves disease-free survival and overall control of the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma laryngeal disorder Mouth Neoplasms oropharynx cancer squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Complejo Hospitalario de Navarra

Pamplona, Navarre, 31008, Spain
Hospital Clinic de Barcelona

Barcelona, Catalonia, 08036, Spain
Hospital Clínico Universitario de Valencia

Valencia, Valencia, 46010, Spain
Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain
Hospital Universitario Valle Hebron

Barcelona, Catalonia, 08035, Spain
Institut Catalá d'Oncologia (ICO) BADALONA

Badalona, Catalonia, 08916, Spain
Institut Catalá d'Oncologia (ICO) Hospitalet

L'Hospitalet de Llobregat, Catalonia, 08908, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.